WO2010012940A3 - Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules - Google Patents

Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules Download PDF

Info

Publication number
WO2010012940A3
WO2010012940A3 PCT/FR2009/051495 FR2009051495W WO2010012940A3 WO 2010012940 A3 WO2010012940 A3 WO 2010012940A3 FR 2009051495 W FR2009051495 W FR 2009051495W WO 2010012940 A3 WO2010012940 A3 WO 2010012940A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral drug
modified release
nanoparticles
drug form
form useful
Prior art date
Application number
PCT/FR2009/051495
Other languages
English (en)
Other versions
WO2010012940A2 (fr
Inventor
Rémi Meyrueix
Rafael Jorda
Anne-Sophie Daviaud
Alain Constancis
Original Assignee
Flamel Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Technologies filed Critical Flamel Technologies
Priority to CN2009801330449A priority Critical patent/CN102131500A/zh
Priority to US12/509,109 priority patent/US20100021549A1/en
Priority to EP09740381A priority patent/EP2317990A2/fr
Priority to JP2011520564A priority patent/JP2011529100A/ja
Priority to CA2731449A priority patent/CA2731449A1/fr
Publication of WO2010012940A2 publication Critical patent/WO2010012940A2/fr
Publication of WO2010012940A3 publication Critical patent/WO2010012940A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention vise à proposer de nouvelles formes orales microparticulaires pour la libération modifiée de principe(s) actif(s), en particulier de nature protéinique ou peptidique. Elle concerne également les applications, notamment thérapeutiques ou cosmétiques, deces formes orales microparticulaires.
PCT/FR2009/051495 2008-07-28 2009-07-24 Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules WO2010012940A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2009801330449A CN102131500A (zh) 2008-07-28 2009-07-24 可用于纳米颗粒的修饰释放的微颗粒口服剂型
US12/509,109 US20100021549A1 (en) 2008-07-28 2009-07-24 Microparticle oral form useful for the modified release of nanoparticles
EP09740381A EP2317990A2 (fr) 2008-07-28 2009-07-24 Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules
JP2011520564A JP2011529100A (ja) 2008-07-28 2009-07-24 ナノ粒子の調節放出に有用な微粒子状経口剤形
CA2731449A CA2731449A1 (fr) 2008-07-28 2009-07-24 Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0855179A FR2934161B1 (fr) 2008-07-28 2008-07-28 Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules.
FR0855179 2008-07-28

Publications (2)

Publication Number Publication Date
WO2010012940A2 WO2010012940A2 (fr) 2010-02-04
WO2010012940A3 true WO2010012940A3 (fr) 2010-03-25

Family

ID=40210723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/051495 WO2010012940A2 (fr) 2008-07-28 2009-07-24 Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules

Country Status (6)

Country Link
EP (1) EP2317990A2 (fr)
JP (1) JP2011529100A (fr)
CN (1) CN102131500A (fr)
CA (1) CA2731449A1 (fr)
FR (1) FR2934161B1 (fr)
WO (1) WO2010012940A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940619B1 (fr) 2008-12-31 2012-02-10 Flamel Technologies Sa Composition comprenant un actif de solubilite aqueuse faible ou moyenne
EP3334776A4 (fr) * 2015-08-13 2019-03-27 The Johns Hopkins University Procédés de préparation de nanoparticules de complexe polyélectrolytique
CN107648182B (zh) * 2016-07-26 2020-03-17 天津大学 超稳定纳米药物载体mPEG-PGlu(D)-VE(D)及制备方法及用途
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
CN111698980A (zh) * 2018-02-06 2020-09-22 3M创新有限公司 具有多孔或中空的芯和pH敏感性壳的微胶囊及其用途
CN109875978A (zh) * 2019-04-12 2019-06-14 常州大学 一种可用于药物缓释的聚丙烯酸-生育酚琥珀酸酯自组装载药体系的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891459A1 (fr) * 2005-09-30 2007-04-06 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2008025425A1 (fr) * 2006-07-28 2008-03-06 Flamel Technologies Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891459A1 (fr) * 2005-09-30 2007-04-06 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2008025425A1 (fr) * 2006-07-28 2008-03-06 Flamel Technologies Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2317990A2 *

Also Published As

Publication number Publication date
CN102131500A (zh) 2011-07-20
CA2731449A1 (fr) 2010-02-04
JP2011529100A (ja) 2011-12-01
FR2934161B1 (fr) 2010-09-17
FR2934161A1 (fr) 2010-01-29
EP2317990A2 (fr) 2011-05-11
WO2010012940A2 (fr) 2010-02-04

Similar Documents

Publication Publication Date Title
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
WO2011049958A3 (fr) Modulation de la température de gélification de formulations contenant des poloxamères
WO2010085100A3 (fr) Nouveau domaine transmembranaire cellulaire et système de transduction intracellulaire contenant ce domaine
WO2009120365A3 (fr) Procédés et compositions pour la délivrance d’agents
WO2012021715A3 (fr) Formulations stables de linaclotide
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
WO2010115552A8 (fr) Anticorps anti-erbb-3/anti-c-met bispécifiques
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2008132229A3 (fr) Solutions et compositions hautement concentrées en insuline
WO2010021607A3 (fr) Préparation pharmaceutique
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
WO2009012871A3 (fr) Capsule filtrant les uv
WO2011017502A3 (fr) Formulations comprenant du linaclotide
WO2006116349A3 (fr) Formulation a liberation prolongee et tableaux de dosage d'inhibiteurs de la synthese de leukotriene pour la therapie humaine
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2010067078A8 (fr) Sels de xanthylium disubstitués en 3 et 6
WO2009089234A3 (fr) Dibenzhydrylpipérazines substituées
WO2011060363A3 (fr) Modulateurs des récepteurs d2 et/ou des récepteurs d3 à base de cyclohexylurée
WO2010012940A3 (fr) Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2010144477A3 (fr) Modulateurs sulfonylurée du récepteur de l'endothéline
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2009114461A3 (fr) Formes pharmaceutiques d'angiotensine (1-7) et leur utilisation
WO2009112590A3 (fr) Substances actives qui augmentent le seuil d'activation de cellules immunitaires
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980133044.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09740381

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009740381

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2731449

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 433/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2011520564

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE